In this double-blind , 3-period , crossover trial , healthy adults ( n = 83 ) received immediaterelease guanfacine ( at therapeutic ( 4 mg ) and supra-therapeutic ( 8 mg ) doses ) , placebo , and 400 mg moxifloxacin ( positive control ) in 1 of 6 randomly assigned sequences .